Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Nov 20, 2026
TickeronGET DAILY SIGNALS
Enlivex Ltd (ENLV) Q3 2026 Earnings: Clinical Milestones Meet Crypto Volatility

Enlivex Ltd (ENLV) Q3 2026 Earnings: Clinical Milestones Meet Crypto Volatility

Key Takeaways

  • Enlivex Ltd (ENLV) is expected to report its third-quarter 2026 results in mid-November 2026, with the three-analyst consensus projecting a net loss of roughly $0.28 per share.
  • As a clinical-stage company, Enlivex is expected to post essentially zero revenue, keeping investor attention on operating expenses, cash burn, and balance-sheet strength.
  • Two distinct value drivers will be in the spotlight: clinical progress on the company's Allocetra immunotherapy and the value of its digital-asset (RAIN token) treasury holdings.
  • A 16-for-1 reverse stock split completed in late October 2026 complicates year-over-year per-share comparisons and has reshaped the stock's trading profile.
  • Recent quarters have been heavily influenced by swings in the value of the company's cryptocurrency-linked holdings, adding unusual volatility to reported earnings.

Why the Upcoming Report Matters

Enlivex Ltd (ENLV) is a clinical-stage biotechnology company headquartered in Israel that has drawn outsized attention not only for its Allocetra immunotherapy pipeline but also for an unconventional treasury strategy built around digital assets, including the RAIN token. That dual identity makes each quarterly report more than a routine update: results can swing sharply depending on the mark-to-market value of the company's cryptocurrency-linked holdings. In its fourth-quarter 2025 report, RAIN token appreciation pushed total assets to roughly $2.31 billion and drove a surge in reported net income. With the upcoming third-quarter 2026 release, investors will weigh clinical milestones against the ongoing volatility of a crypto-exposed balance sheet. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

What Analysts Are Projecting

Analysts tracked by major financial data providers project a net loss of approximately $0.28 per share for the third quarter of 2026, based on a three-analyst consensus. On a reverse-split-adjusted basis following the 16-for-1 share consolidation completed in late October 2026, that estimate translates to a materially larger per-share loss, underscoring how the reverse split distorts straightforward comparisons. Revenue is expected to be negligible, as the company has no commercialized product generating sales.

Investors will therefore focus less on top-line figures and more on research and development (R&D) spending, general and administrative costs, and the company's cash position. Prior quarters offer a cautionary backdrop: the fourth quarter of 2025 delivered net income of roughly $1.23 billion and diluted earnings per share (EPS, profit divided by outstanding shares) of about $25.48, driven almost entirely by RAIN token appreciation, and the stock rose roughly 15.79% following that report. By contrast, more recent quarters have shown a return to operating losses, reflecting the unpredictable influence of the digital-asset treasury.

Market Reaction and Investor Sentiment

Sentiment heading into the third-quarter 2026 report is unusually mixed. On one hand, Enlivex's FDA-cleared Phase IIb osteoarthritis trial for Allocetra gives long-term investors a tangible clinical catalyst to track. On the other, the company's exposure to digital-asset volatility has introduced a level of price unpredictability rarely seen in traditional biotech names. The late-October reverse stock split further muddied the picture, changing share counts and per-share metrics at a time when investors were already parsing unusually large swings in reported earnings. Heading into the release, traders are likely to remain sensitive both to any updates on clinical timelines and to the current value of the company's token holdings, making the market reaction difficult to predict from operating results alone. From what I see, this tension is what makes the stock particularly interesting to follow.

Forward Outlook and Key Factors to Monitor

Beyond the immediate earnings print, several factors will shape how investors evaluate Enlivex going forward.

First, the Allocetra clinical program remains the core fundamental story. With the FDA (U.S. Food and Drug Administration) having cleared a Phase IIb osteoarthritis trial and top-line data expected in 2027, any commentary on enrollment progress, timelines, or additional indications will be closely watched.

Second, the digital-asset treasury will continue to inject volatility into reported results. The value of RAIN token holdings can swing sharply between quarters, meaning headline net income may diverge dramatically from underlying operating performance. Investors should distinguish operating losses from treasury-driven gains or losses.

Third, liquidity and capital structure deserve attention. The company completed a $21 million debt financing and previously reported a strong current ratio (a measure of short-term liquidity comparing current assets to current liabilities) of about 6.43. Combined with the recent reverse split, these items may influence how the company funds future trials and manages its balance sheet.

Finally, cash burn remains a key metric. With no meaningful revenue, R&D spending will dictate how long existing resources last and whether additional financing could eventually dilute shareholders. Watching these elements together, rather than any single headline number, will offer the clearest picture of Enlivex's trajectory. I’m watching this closely as the clinical and treasury elements evolve.

Using AI Tools in My Research

In preparing for earnings seasons like this one, I often turn to Tickeron’s AI Screener to quickly filter for stocks with similar volatility profiles or technical setups. It helps surface relevant patterns without spending hours on manual screening, which is especially handy when balancing biotech catalysts with crypto-related swings. The tool has become a regular part of how I cross-check ideas before digging deeper into individual filings.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ENLV

Contributor

My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.


ENLV in upward trend: price may jump up because it broke its lower Bollinger Band on October 30, 2026

ENLV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 35 cases where ENLV's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 59 of 69 cases where ENLV's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.

Following a +9.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where ENLV advanced for three days, in 158 of 198 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENLV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for ENLV entered a downward trend on November 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.006) is normal, around the industry mean (3.596). P/E Ratio (0.001) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. ENLV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENLV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -9%. For the same Industry, the average monthly price growth was -16%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 111%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 84%. For the same stocks of the Industry, the average monthly volume growth was 101% and the average quarterly volume growth was 38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 68
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions

Industry Biotechnology

Industry
Medical Specialties
Address
14 Einstein Street
Phone
+972 86328500
Employees
34
Web
https://www.enlivex.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.